Imada Hiroshi, Kawakami Kazuyoshi, Hiraoka Tomoko, Higuchi Shutaro, Takahashi Gou, Aoyama Takeshi, Shinozaki Eiji, Suenaga Mitsukuni, Matsuzaka Satoshi, Hama Toshihiro
Department of Pharmacy, Cancer Institute Hospital.
Gan To Kagaku Ryoho. 2007 Sep;34(9):1425-30.
We have been collecting data on the adverse reaction of FOLFOX 4 chemotherapy in our hospital from April 2005 to October retrospectively, by electronic clinical records. A retrospective study of 123 patients receiving FOLFOX 4 for advanced colorectal cancer was conducted. Survey results showed high incidences of hemotoxicity (52.8%), chronic sensory neuropathy (16.2%) and allergic reactions (15.4%). In the initial FOLFOX 4 therapy, appetite loss (60.1%), vomiting (19.5%) and acute sensory neuropathy (33.3%) were observed. We prepared a brochure in order to minimize inter-individual differences in pharmaceutical care and drug consultation by clinical pharmacists and to ensure the accurate understanding of patients. We feel sure that this kind of activity will help us to provide better pharmaceutical care for patients.
我们通过电子临床记录，回顾性收集了2005年4月至10月我院接受FOLFOX 4化疗的不良反应数据。对123例接受FOLFOX 4治疗晚期结直肠癌的患者进行了回顾性研究。调查结果显示血液毒性（52.8%）、慢性感觉神经病变（16.2%）和过敏反应（15.4%）的发生率较高。在初始FOLFOX 4治疗中，观察到食欲减退（60.1%）、呕吐（19.5%）和急性感觉神经病变（33.3%）。我们编写了一本手册，以尽量减少临床药师在药学服务和药物咨询中的个体差异，并确保患者的准确理解。我们确信这种活动将有助于我们为患者提供更好的药学服务。
